SCHEMBL28697219

SCHEMBL28697219

CC(C)(C)OC(=O)Nc1cccc(O)c1F

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 1/20 0.47
HSP90AA1 P07900 1/20 0.46
HSP90AB1 P08238 1/20 0.46
LMNA P02545 2/20 0.45
POLB P06746 1/20 0.45
METAP1 P53582 1/20 0.41
KCNQ4 P56696 1/20 0.40
KCNQ5 Q9NR82 1/20 0.40
GAA P10253 1/20 0.40
MAPT P10636 1/20 0.40
HTT P42858 1/20 0.40
BRD9 Q9H8M2 1/20 0.40
CYP17A1 P05093 1/20 0.39
SYK P43405 1/20 0.39
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
RAB9A P51151 2/20 0.38
NPC1 O15118 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
LCK P06239 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28707071 0.86 CYP17A1 (0.43) RXFP1HSP90AA1HSP90AB1LMNAPOLB
SCHEMBL28856066 0.84 RXFP1 (0.47) RXFP1LMNAPOLBMETAP1KCNQ4
SCHEMBL2940952 0.83 GAA (0.51) RXFP1HSP90AA1HSP90AB1LMNAPOLB
SCHEMBL29991642 0.83 RXFP1 (0.46) RXFP1HSP90AA1HSP90AB1LMNAPOLB
SCHEMBL575004 0.83 RXFP1 (0.46) RXFP1HSP90AA1HSP90AB1LMNAPOLB
SCHEMBL29909461 0.83 RXFP1 (0.46) RXFP1HSP90AA1HSP90AB1LMNAPOLB
SCHEMBL29286688 0.83 RXFP1 (0.46) RXFP1HSP90AA1HSP90AB1LMNAPOLB
SCHEMBL12517737 0.83 RXFP1 (0.46) RXFP1HSP90AA1HSP90AB1LMNAPOLB
SCHEMBL29448807 0.83 RXFP1 (0.46) RXFP1HSP90AA1HSP90AB1LMNAPOLB
SCHEMBL27913236 0.83 RXFP1 (0.46) RXFP1HSP90AA1HSP90AB1LMNAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114144410-A Polyarylurea derivatives and their use in the treatment of muscular diseases 阿纳格纳斯生物技术股份有限公司 2022-03-04 CN disclosed